semaglutide for hfpef Symptom Management in and Related Metabolic Phenotypes ESC 2025: study supports use

Curr Neuropharmacol 15(4):519533

Hippen: In particular some of the studies with the GLP-1 agonists that both have a renal secondary endpoint as well as a study we'll talk about in a minute that is actually focused on a renal primary endpoint postulates that these patients are not only on full RAS inhibition in addition to the drug under study, but that they're on full RAS inhibition as well as the GLP-1 agonist for a period of years to realize the benefits that we're looking forward to hearing the reports of in the forthcoming months

Therefore, it is interesting that 2-AAA was decreased in the group with L-carnitine administration, as it suggested a possible decrease in risk for diabetes

By activating these receptor systems, researchers can investigate mechanisms involved in satiety signaling and metabolic regulation